BOC Sciences has been constantly enriching its peptide product library for years. Its peptides for diabetes research are recently brought into focus due to the growing concerns on this problem.
According to data from the WHO, a large number of adults are having diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia. The absolute lack of insulin, due to destruction of the insulin producing pancreatic β-cells, is the particular disorder in type 1 diabetes while type 2 diabetes is mainly characterized by the inability of cells to respond to insulin.
As one of the most challenging health problems of the 21st century, diabetes has been investigated for years with many promising drugs and therapies springing up. Some technologies about peptides have gained much attention since certain peptide drugs are proved to significantly promote insulin secretion and help restore the function of pancreatic beta cells.
BOC Sciences, the world-leading biotech company, has also made its exclusive contribution by offering a series of peptides for diabetes research. BOC Sciences now adds quite a number of diabetes peptides to its collection, i.e., amylin (IAPP) & analogs, exendin & analogs, ghrelin & analogs, C-peptide, gastric inhibitory polypeptide (GIP), etc.
The list is too long to be enumerated. The chief technician of BOC Sciences expatiates some information about C-peptide as an example, “Our C-peptide can alleviate and delay the occurrence and development of chronic complications such as kidney, nerve, and cardiovascular in patients with type 1 diabetes by activating some enzymes, which provides a new solution to the treatment of type 1 diabetes.”
Some peptides in the BOC Sciences inventory are also valued as critical tools in the R&D of drugs for type 2 diabetes. For instance, islet amyloid polypeptide (IAPP), a major component of the pancreatic amyloid deposits found in the pancreas of patients with type 2 diabetes, may be involved in the pathogenesis of type 2 diabetes. IAPP is now evidenced to lower blood sugar by reducing postprandial glucagon secretion, delaying gastric emptying, and suppressing appetite. BOC Sciences generally prepares IAPP by genetic engineering and then supplies them to customers specializing in the clinical treatment of type 2 diabetes. More broadly, some IAPP analogs, i.e., pramlintide also show positive effects as adjunctive drugs for type 1 diabetes.
Accompanied by the rising attention to diabetes therapeutics, BOC Sciences also invests equal or even more energy in developing peptides & analogs for diabetes. More information can be accessed at our website.
With years of experience in peptide manufacturing and synthesis, BOC Sciences has made commendable achievements in custom peptide synthesis and production. Presently, its peptide products can be applied in the treatment of multiple diseases (diabetes, cancer, Alzheimer’s disease, HIV, HPV, etc.) and have very good curative effects.